Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (14255)	7/28/2000 8:48:03 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Cacaito, Xoma has done alot of reseach and testing of BPI and now Baxter has control of BPI for systemic realm per se. Where it goes now is up to Baxter isn't it??? Why don't we wait and see what indication Baxter picks? Will they tweak trauma??? Will there be a cross over bridge trial in Meningo??? Will Baxter go for approval in Europe??? In the meantime Xoma has laid some ground work in the patent areas. In the meantime Xoma has anti-cd11a with Genentech. Piper took a look at Xoma and gave an opinion. What would you have them do WAIT until new developments to give their analyst's opinion? To tell you the truth I am bored with all of this and we are just going around in circles. I have tried once to suggest we try to move on. You, most important are wasting your brainpower on this nonsense. No way are you going to convince me that Bpi is worthless. Keep in mind also that hopefully no one has put more money in ANY Biotech they cannot afford to lose. Biotechs as you know are as risky as they come and most have no earnings. VERY RISKY. BTW, I see your ICOS is WELL off its 52 week high. Why??? Baxter is very near it's 52 week high??? Why?? Only my opinions.